Photo Gallery



News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  • FEBRUARY 2020 Issue has been successfully launched on 1 February 2020.

  • WJPPS Impact Factor
  • Its our Pleasure to Inform you that WJPPS Impact Factor has been increased from  7.454 to 7.632  due to high quality Publication at International Level

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level



Sanoop J.*, Sara Yeldhos and Priyanka S.



Background: Proton pump inhibitors are one of the widely prescribed classes of drugs in the world and are mainly used in treating Gastritis, Peptic ulcer, and Gatroesophageal reflux disease but nowadays these drugs are widely used in combination with NSAIDs to counteract its side effects. There is a huge number of marketed drugs available for proton pump inhibitors in India and differential pricing of the branded drugs can lead to decreased compliance and increased morbidity and also places an economic burden on the patient and it also affects the health seeking behaviour of the patient. Hence this study was done to analyse the cost minimization and cost variation of different brands of Proton pump inhibitors available in Indian pharmaceutical market. Materials and methods: The cost of the drugs are obtained from CIMS, July to Oct, 2019, and cost range, mean cost, cost ratio and percentage cost variation for individual drug brands was calculated. The cost of 10 tablets or capsules and 1 vial/ampoule was taken in case of oral and parenteral preparations respectively. Results: There is a gross variation in the prices of branded drugs of proton pump inhibitors in India. The highest cost range is for oral Rabeprazole 20mg (114.10) and mean cost is for IV Esomeprazole 40mg (115.25). The highest cost ratio and percentage price variation is for IV Pantoprazole 40mg (31.22, 3022.36). Conclusions: Prescribers should be aware of the differential pricing of the branded drugs and clinical pharmacists are at a position to ensure cost effective treatment by intervening wherever clinically relevant to attain optimum healthcare and economic benefits to the patient.

Keywords: PPIs, Cost minimization analysis, Cost ratio, Percentage cost variation, Compliance.

[Full Text Article]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More